A phase I study of doxorubicin-loaded anti-EGFR immunoliposomes in patients with advanced solid tumors.
C. Mamot
Stock Ownership - LipoTarg GmbH
R. Ritschard
No relevant relationships to disclose
B. Vogel
No relevant relationships to disclose
T. Dieterle
No relevant relationships to disclose
L. Bubendorf
No relevant relationships to disclose
C. Hilker
No relevant relationships to disclose
S. Deuster
No relevant relationships to disclose
R. Herrmann
Employment or Leadership Position - LipoTarg GmbH (U)
Stock Ownership - LipoTarg GmbH
C. Rochlitz
Stock Ownership - LipoTarg GmbH